Sanofi's bid yesterday for SOBI's partner Bioverativ at a 60%+ premium is highly supportive for SOBI's valuation. Strong future in haemophilia products Eloctate and Alprolix. As the European territory (SOBI territory) launches were two years later than the US, SOBI's sales are at an earlier stage, and there is strong growth potential as the products move closer to...